Mavacamten in Patients With Hypertrophic Cardiomyopathy Referred for Septal Reduction: Week 56 Results From the VALOR-HCM Randomized Clinical Trial
RCT (n=108) showed that in patients with symptomatic obstructive hypertrophic cardiomyopathy, mavacamten reduced the need for septal reduction therapy at week 56, with sustained improvements in left ventricular outflow tract gradients and symptoms.
Source:
JAMA Cardiology
SPS commentary:
Editorial discusses mavacamten as a first in class cardiac myosin inhibitor, a novel class of drugs developed to target the underlying molecular defect of hyperactivation of the cardiac sarcomere in patients with hypertrophic cardiomyopathy (HCM). Mavacamten, received FDA approval in 2022 following results of the EXPLORER-HCM trial which reported significant reductions in left ventricular outflow tract gradients, improvement in New York Heart Association classification, and improvement in exercise capacity compared with placebo in symptomatic patients with obstructive HCM. It notes the similarities in results of this study with previous studies.
Also published in the journal are data from the EXPLORER-CN study, which evaluated the safety and efficacy of mavacamten compared with placebo in 81 Chinese patients with symptomatic obstructive hypertrophic cardiomyopathy. The study reported improved Valsalva left ventricular outflow tract obstruction compared with placebo.